FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036362007> ?p ?o ?g. }

• W3036362007 abstract "ABSTRACT Objective To evaluate the comparative efficacy and safety of pharmacological interventions used in treating COVID-19 and form a basis for an evidence-based guideline of COVID-19 management by evaluating the level of evidence behind each treatment regimen in different clinical settings. Design Systematic review and network meta-analysis Data Sources PubMed, Google Scholar, MEDLINE, the Cochrane Library, medRxiv, SSRN, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov up to June 9 th , 2020. Study Selection Published and unpublished randomized controlled trials (RCTs) and baseline-adjusted observational studies which met our predefined eligibility criteria. Main Outcome Measures The outcomes of interest were mortality, progression to severe disease (severe pneumonia or admission to intensive care unit (ICU)), time to viral clearance, QT prolongation, fatal cardiac complications, and non-cardiac serious adverse events. The level of evidence behind each outcome was also measured using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Results 49 studies with a total of 20212 confounder-adjusted patients were included for analysis. The risk of progression to severe pneumonia or ICU admission was significantly reduced with tocilizumab (GRADE low), anakinra (GRADE very low), and remdesivir (GRADE high) compared to standard care. Tocilizumab was shown to reduce mortality rate for both moderate-severe patients in the non-ICU setting at admission (Odds ratio (OR) 0.31, 95% confidence interval (CI) 0.18 to 0.54, GRADE low) and critically ill patients in the ICU setting (OR 0.67, 95% CI 0.50 to 0.91, GRADE low). High dose IVIG reduced death rate (GRADE low) while corticosteroids increased mortality for critically ill patients (GRADE moderate). Convalescent plasma and hydroxychloroquine were shown to promote viral clearance (OR 11.39, 95% CI 3.91 to 33.18, GRADE low and OR 6.08, 95% CI 2.74 to 13.48, GRADE moderate, respectively) while not altering mortality or progression to the severe courses. The combination of hydroxychloroquine and azithromycin was shown to be associated with increased QT prolongation incidence (OR 1,85, 95% CI 1.05 to 3.26, GRADE low) and fatal cardiac complications in cardiac-impaired populations (OR 2.26, 95% CI 1.26 to 4.05, GRADE low). High-dose (>600mg/day) hydroxychloroquine monotherapy was significantly associated with increased non-cardiac serious adverse events (GRADE moderate). Conclusion Anti-inflammatory agents (tocilizumab, anakinra, and IVIG) and remdesivir may safely and effectively improve outcomes of hospitalized COVID-19 patients. Widely used hydroxychloroquine provides marginal clinical benefit in improving viral clearance rates whilst posing both cardiac and non-cardiac safety risks, especially in the vulnerable population. Only 20% of current evidence on pharmacological management of COVID-19 is on moderate and high evidence certainty and can be considered in practice and policy; remaining 80% are of low or very low certainty and warrant further studies to establish firm conclusions. Systematic Review Registration PROSPERO 2020: CRD42020186527. Summary Box Section 1: What is already known on this topic - Numerous clinical trials and observational studies have investigated various pharmacological agents as potential treatment for COVID-19. - Results from numerous studies are heterogeneous and sometimes even contradictory to one another, making it difficult for clinicians to determine which treatments are truly effective. - Level of evidence behind each outcome from diverse studies remains unknown. Section 2: What this study adds - Anti-inflammatory agents (tocilizumab, anakinra, and IVIG) and remdesivir may safely and effectively improve clinical outcomes of COVID-19. - Widely used hydroxychloroquine provides marginal clinical benefit in improving viral clearance rates whilst posing both cardiac and non-cardiac safety risks. - Only 20% of current evidence on pharmacological management of COVID-19 is on moderate/high evidence certainty and can be considered in practice and policy; remaining 80% are of low or very low certainty and warrant further studies to establish firm conclusions." @default.
• W3036362007 created "2020-06-25" @default.
• W3036362007 creator A5035770769 @default.
• W3036362007 creator A5054993337 @default.
• W3036362007 creator A5066566375 @default.
• W3036362007 creator A5073130641 @default.
• W3036362007 date "2020-06-19" @default.
• W3036362007 modified "2023-10-02" @default.
• W3036362007 title "Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis of confounder-adjusted 20212 hospitalized patients" @default.
• W3036362007 cites W1487246189 @default.
• W3036362007 cites W1498847688 @default.
• W3036362007 cites W1537972189 @default.
• W3036362007 cites W1595166238 @default.
• W3036362007 cites W1969421278 @default.
• W3036362007 cites W1995777506 @default.
• W3036362007 cites W2026404803 @default.
• W3036362007 cites W2033710277 @default.
• W3036362007 cites W2075535893 @default.
• W3036362007 cites W2091808438 @default.
• W3036362007 cites W2095898737 @default.
• W3036362007 cites W2096445424 @default.
• W3036362007 cites W2111999709 @default.
• W3036362007 cites W2120852203 @default.
• W3036362007 cites W2126194308 @default.
• W3036362007 cites W2126930838 @default.
• W3036362007 cites W2130048482 @default.
• W3036362007 cites W2133531206 @default.
• W3036362007 cites W2136732030 @default.
• W3036362007 cites W2149611072 @default.
• W3036362007 cites W2150952126 @default.
• W3036362007 cites W2155798268 @default.
• W3036362007 cites W2162732991 @default.
• W3036362007 cites W2170892587 @default.
• W3036362007 cites W2531269403 @default.
• W3036362007 cites W2575452307 @default.
• W3036362007 cites W2625450956 @default.
• W3036362007 cites W2742200330 @default.
• W3036362007 cites W2750414845 @default.
• W3036362007 cites W2766765254 @default.
• W3036362007 cites W2780507997 @default.
• W3036362007 cites W2785418475 @default.
• W3036362007 cites W2789572026 @default.
• W3036362007 cites W2898577363 @default.
• W3036362007 cites W2914055690 @default.
• W3036362007 cites W2957311488 @default.
• W3036362007 cites W2970485705 @default.
• W3036362007 cites W3009859788 @default.
• W3036362007 cites W3012421327 @default.
• W3036362007 cites W3012849736 @default.
• W3036362007 cites W3012978629 @default.
• W3036362007 cites W3014524604 @default.
• W3036362007 cites W3015107971 @default.
• W3036362007 cites W3015321334 @default.
• W3036362007 cites W3022504328 @default.
• W3036362007 cites W3025795175 @default.
• W3036362007 cites W3032824264 @default.
• W3036362007 cites W3035365037 @default.
• W3036362007 cites W3119734014 @default.
• W3036362007 doi "https://doi.org/10.1101/2020.06.15.20132407" @default.
• W3036362007 hasPublicationYear "2020" @default.
• W3036362007 type Work @default.
• W3036362007 sameAs 3036362007 @default.
• W3036362007 citedByCount "3" @default.
• W3036362007 countsByYear W30363620072020 @default.
• W3036362007 crossrefType "posted-content" @default.
• W3036362007 hasAuthorship W3036362007A5035770769 @default.
• W3036362007 hasAuthorship W3036362007A5054993337 @default.
• W3036362007 hasAuthorship W3036362007A5066566375 @default.
• W3036362007 hasAuthorship W3036362007A5073130641 @default.
• W3036362007 hasBestOaLocation W30363620071 @default.
• W3036362007 hasConcept C126322002 @default.
• W3036362007 hasConcept C142724271 @default.
• W3036362007 hasConcept C156957248 @default.
• W3036362007 hasConcept C168563851 @default.
• W3036362007 hasConcept C17744445 @default.
• W3036362007 hasConcept C177713679 @default.
• W3036362007 hasConcept C189708586 @default.
• W3036362007 hasConcept C199539241 @default.
• W3036362007 hasConcept C23131810 @default.
• W3036362007 hasConcept C2776376669 @default.
• W3036362007 hasConcept C2776478404 @default.
• W3036362007 hasConcept C2777178219 @default.
• W3036362007 hasConcept C2777914695 @default.
• W3036362007 hasConcept C2779134260 @default.
• W3036362007 hasConcept C2779473830 @default.
• W3036362007 hasConcept C2780182762 @default.
• W3036362007 hasConcept C44249647 @default.
• W3036362007 hasConcept C535046627 @default.
• W3036362007 hasConcept C71924100 @default.
• W3036362007 hasConcept C95190672 @default.
• W3036362007 hasConceptScore W3036362007C126322002 @default.
• W3036362007 hasConceptScore W3036362007C142724271 @default.
• W3036362007 hasConceptScore W3036362007C156957248 @default.
• W3036362007 hasConceptScore W3036362007C168563851 @default.
• W3036362007 hasConceptScore W3036362007C17744445 @default.
• W3036362007 hasConceptScore W3036362007C177713679 @default.
• W3036362007 hasConceptScore W3036362007C189708586 @default.
• W3036362007 hasConceptScore W3036362007C199539241 @default.
• W3036362007 hasConceptScore W3036362007C23131810 @default.
• W3036362007 hasConceptScore W3036362007C2776376669 @default.

• next